- Muling isasailalim sa iskedyul ang cannabis bago ang Disyembre 31?11¢11%
The DEA administrative process for moving botanical marijuana from Schedule I to Schedule III remains in a limited briefing phase following an October 22 order from Chief ALJ Derek Julius. That ruling admitted a September GAO report highlighting gaps in federal scheduling procedures but denied requests to reopen the June-July 2026 hearings for additional testimony. Optional briefs on the report’s weight are due by November 5, after which the stay lifts and the judge can issue a nonbinding recommendation. An April 2026 Attorney General order already placed state-licensed medical marijuana and FDA-approved products into Schedule III, with the DEA issuing initial federal registrations to over 900 dispensaries in seven states as the first implementation step. Broader rescheduling covering adult-use cannabis requires the full hearing record, agency decision, and potential further review, keeping near-term resolution unlikely.
Mga panuntunan
Maresolba ang market na ito bilang "Oo" kung ibababa ng Drug Enforcement Administration ng Estados Unidos (https://www.dea.gov/drug-information/drug-scheduling) ang klasipikasyon ng marijuana mula sa Iskedyul I tungo sa anumang ibang antas (o tuluyan itong aalisin sa listahan ng mga kontroladong sangkap) pagsapit ng Disyembre 31, 2026, 11:59 PM ET. Kung hindi, maresolba ang market na ito bilang "Hindi". Ang pangunahing mapagkukunan para sa resolusyon ng market na ito ay ang opisyal na impormasyon mula sa gobyerno ng US; gayunman, gagamitin din ang pinagkaisahang ulat mula sa mga mapagkakatiwalaang pinagmulan.
Awtomatikong salin. Kapag may alitan, ang orihinal ang masusunod.